Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11520 posts found.

ai_graphic

Key legal considerations in accelerating pharma using artificial intelligence

September 4, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, artificial intelligence, pharma

Charlotte Walker-Osborn, Partner and International Technology Sector Head and Nabil Asaad, Senior Associate, Intellectual Property Law Group – both from …
Feature
w3_banners6

FREE WEBINAR: Leveraging technology for optimal engagement

September 4, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, Webinar, Within3, pharma

Join Pharmafocus and Within3 for a special webinar event on Thursday, 19 September, for a session exploring the changing trends …
News
merckwindow_web

Keytruda scores EU approval in combination with Inlyta for first-line advanced renal cell carcinoma

September 4, 2019 Research and Development, Sales and Marketing EU, Europe, MSD, keytruda, pharma, renal cell carcinoma

The European Commission has awarded yet another authorisation in the region to MSD’s Keytruda, this time in combination with the …
News

NICE recommends Novartis’ gene therapy Luxturna for inherited retinal dystrophy

September 4, 2019 Research and Development, Sales and Marketing Luxturna, NHS, NICE, UK, gene therapy, pharma

NICE has chosen to recommend the use of Novartis’ one-time gene therapy Luxturna (voretigene neparvovec) for use on the NHS …
News
astrazeneca_plaque

AZ’s Tagrisso secures China approval in first-line advanced lung cancer

September 4, 2019 Research and Development, Sales and Marketing AstraZeneca, China, Tagrisso, lung cancer, pharma

AstraZeneca’s Tagrisso (osimertinib) has secured approval in China from the country’s National Medical Products Administration (NMPA) in the first-line treatment …
News
sandoz

Sandoz acquires global commercialisation rights to Polpharma’s multiple sclerosis biosimilar

September 3, 2019 Manufacturing and Production, Sales and Marketing Polpharma, Sandoz, biosimilar, multiple sclerosis, pharma

Sandoz has revealed that it has sealed a deal with Polpharma Biologics to commercialise the latter’s proposed biosimilar version of …
News
mylan_building

Mylan gets provisional FDA greenlight for generic version of Lilly’s blockbuster cancer drug Alimta

September 2, 2019 Sales and Marketing Alimta, Cancer, Eli Lilly, FDA, Mylan, pharma

Mylan has scored a preliminary approval in the US from the FDA for its generic version of Eli Lilly’s blockbuster …
News
brexit_flag

No-deal Brexit will “make the disintegration of the health service an ever more real prospect”, BMA warns

September 2, 2019 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMA, NHS, UK, brexit, pharma

As the UK hurtles towards a catastrophic and autocratic exit from the European Union, the British Medical Association (BMA) has …
News
astrazeneca-sign

AstraZeneca presents strong Phase 3 Brilinta data for reducing CV risk

September 2, 2019 Research and Development, Sales and Marketing AstraZeneca, Brilinta, pharma

AstraZeneca has unveiled new positive Phase 3 data on the efficacy of Brilinta (ticagrelor) in combination with aspirin, showing that …
News
novartis_outside_1

Novartis’ Entresto narrowly misses Phase 3 goal in heart failure patients

September 2, 2019 Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma

New Phase 3 data for Novartis’ Entresto (sacubitril/valsartan) have been released, showing that the therapy narrowly missed its primary endpoint …
News
roche

Roche’s Xofluza reduces risk of catching flu by 86% in Phase 3 trial

September 2, 2019 Research and Development, Sales and Marketing Roche, Xofluza, flu, influenza, pharma

Roche has brought forward new Phase 3 data on Xofluza (baloxavir marboxil), proving the therapy’s efficacy in the preventative treatment …
News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

August 30, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top 10

Happy Friday! It’s time for another rundown of the top 10 most popular articles with Pharmafile.com readers this week.10. NICE …
News
roche__tree

Roche’s Tecentriq combo becomes first EU-approved immunotherapy for triple-negative breast cancer

August 30, 2019 Medical Communications, Sales and Marketing EMA, Europe, Roche, breast cancer, pharma, tecentriq

Roche has announced the approval of Tecentriq (atezolizumab), in combination with Celgene’s chemotherapy drug Abraxane (nab paclitaxel), by the European …
News
real_world

Using advanced digital capabilities to unlock hard-to-see HCPs access

August 29, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing digital pharma, pharma, veeva

Pharmaceutical companies face a ‘digital imperative’ to engage with healthcare professionals through their channel preferences and ensure they are getting …
News
alexion_solirispackaging

Alexion’s Soliris scoops up expanded EU approval in neuromyelitis optica spectrum disorder

August 28, 2019 Research and Development, Sales and Marketing Alexion, FDA, US, pharma, soliris

Alexion has announced the expanded EU approval of Soliris (eculizumab) as a treatment for neuromyelitis optica spectrum disorder (NMOSD) in …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025